The genome,
read with care.
From sequencing chemistry and ACMG variant calling to methylation clocks, polygenic prediction, and the CRISPR drugs already on pharmacy shelves — taught with claim-grading, ancestry-aware caveats, and three tracks for every clinician.
Choose your depth
Switch tracks anytime in the sidebar. Lessons reveal a foundations explainer, a clinician deep-dive, and an advanced research note depending on your selection.
Genome architecture, sequencing technology, and the variant-interpretation framework — for any clinician encountering genomic data.
Diagnostic ordering, ACMG variant classification, pharmacogenomics, cancer genomics, and counseling — for prescribers and genetic counselors.
Polygenic prediction, methylation clocks, CRISPR/base/prime editing, in-vivo delivery, and the regulatory frontier — for translational researchers and specialists.
From base pairs to bedside
The course — and this site — is organised around the three jobs a clinician actually does with a genome: read it, watch it, and act on it.
Sequencing chemistry, ACMG variant calling, ancestry-aware caveats, and the evidence grade behind every claim. Learn to read a report without overreading it.
Hereditary panels, NIPT, pharmacogenomics, ctDNA/MRD, polygenic risk, and methylation clocks — what they catch early, what they miss, and what they oversell.
Approved CRISPR, base/prime editing, AAV, ASO, siRNA, mRNA, and engineered cells. Casgevy, Zolgensma, and the base-editor pivotals — staged by trial maturity.
9 modules unlocked
This isn't another "23andMe explained" deck.
The audience is clinicians and translational researchers working with real reports. Casgevy ships at $2.2 M, ctDNA MRD changes adjuvant decisions in colorectal cancer, methylation episignatures resolve previously undiagnosable intellectual disability, base editors are in pivotal cardiovascular trials. We teach the substrate, the evidence grade, and the things being oversold — including by the field's own enthusiasts.